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Dibenz[a,h]anthracene (DB[a,h]A)
is a by-product of incomplete combustion of organic matter and is found in various environmental mixtures including coal tar, coke oven emissions, cigarette smoke, petroleum refinery emissions, vehicular exhaust and residential coal and oil stoves (1) . DB [a,h] A is classified as a probable human carcinogen by the International Agency for Research on Cancer (2) . Although DB[a,h]A is generally biologically inert, it can be activated enzymatically by cytochrome P450-dependent monooxygenases (CYPs) to produce a highly reactive 3,4-diol-1,2-epoxide. The interaction of this metabolite and the nucleophilic centres of nucleic acids can result in the formation of DNA adducts that can cause DNA sequence mutations (1, (3) (4) (5) .
The majority of research on environmental polycyclic aromatic hydrocarbons (PAHs) has focussed on benzo[a]pyrene (B[a]P), with less effort to fully characterise the effects of compounds such as DB[a,h]A. However, studies on air in urban/industrialised areas of various developed countries demonstrate that B[a]P and DB [a,h] A are among the two largest contributors to the carcinogenicity of environmental mixtures (6, 7) . Animal studies indicate that the carcinogenic potency of DB[a,h]A is 10 (or more) times greater than B[a]P (1) . DB [a,h] A is also one of the 16 PAHs designated as priority pollutants by the United States Environmental Protection Agency (i.e. US EPA), which were highlighted for concern and control (8) . Because of its importance in the carcinogenicity of environmental mixtures, it is essential to have a clear understanding of the potential modes of action by which DB[a,h]A operates to elicit carcinogenicity and how these may compare with other priority PAHs.
Detailed in vivo characterisation of the biological functions and processes perturbed by DB[a,h]A has not been conducted. In addition, the mechanism(s) underlying the higher carcinogenic potency of DB[a,h]A relative to B[a]P is/are not fully elucidated. It has been suggested that DB[a,h]A has a higher affinity for the aryl hydrocarbon receptor (AhR) than B[a]P, which could contribute to differences in the carcinogenic potential of the two chemicals (9) . Toxicogenomics provides a powerful platform for investigating the molecular processes and biological functions that are perturbed during chemical toxicity. Analysis of the effects of DB[a,h]A on global gene expression relative to B[a]P would provide valuable insight into the toxic potential and mechanisms of action of this priority PAH.
In this study, we exposed Muta ™ Mouse males orally to three doses of DB[a,h]A (6.25, 12.5, 25 mg/kg/day) daily for 28 days. DNA adduct levels and Muta ™ Mouse transgene mutant frequencies were quantified to confirm delivery of a mutagenic dose of DB [a,h] A to the liver. Immunohistochemistry studies were used to measure cell proliferation. Hepatic microRNA (miRNA) and mRNA expression profiles resulting from DB[a,h]A exposure were investigated to explore the toxicological effects and potential modes of action of this chemical. The toxicogenomic profiles were compared with data derived from male Muta ™ Mouse exposed previously to B[a]P using an identical experimental design (10) . Finally, an in vitro chemical-activated luciferase expression (CALUX) assay was employed to measure AhR agonism for both chemicals using a mouse hepatoma cell line containing a luciferase reporter gene (H1L1.1c2). ™ Mouse (n = 5 per group) males were treated with 0, 25, 50 or 75 mg/kg/day B[a]P in olive oil for 28 days using a similar experimental regime. The details of this study were published previously and are described by Malik et al. (10) .
Immunohistochemistry
Formalin-fixed liver samples were embedded in paraffin the day following necropsy and the resulting formalin-fixed paraffin-embedded tissues were sectioned to 4-µm-wide slices. Tissue slices were mounted on slides and dried overnight. The slides were analysed for cell proliferation (ki67) using ki67 antibody (clone TEC-3) (DAKO, Burlington, ON). All slides were visualised on a Leica DM 4500 B microscope equipped with an Olympus DP 70 camera. Image acquisition and data analysis were conducted using Visiopharm Integrator System (v.3.2.8.0, Hoersholm, Denmark). Ki67 index (i.e. proliferation index) was calculated as the frequency of ki67-positive stained cells. Statistical analysis was conducted with SAS v9.2 using ordinary least-squares analysis of variance with post hoc contrasts for each dose group compared with control using a one-way Dunnett test.
DNA adduct analysis DNA was isolated from minced tissue derived from the right and median liver lobes of B[a]P-and DB[a,h,]A-treated mice using a standard phenol/chloroform extraction method. The nuclease P1 digestion enrichment version of the 32 P-post-labelling assay was used to measure DNA adduct formation in all samples. The procedure was performed essentially as described previously (12, 13) with some minor modifications; digestion of 4 μg of DNA was conducted overnight using micrococcal nuclease (288 mUnits, Sigma, Gillingham, UK) and calf spleen phosphodiesterase (1.2 mUnits, MP Biomedicals Europe, Illkirch Cedex, France).
lacZ mutant frequency
The P-Gal (phenyl-β-d-galactoside) positive selection assay, as described previously, was used to determine the frequency of lacZ transgene mutants in hepatic DNA samples (11, 14) . The Transpack TM lambda packaging system (Agilent Technologies, Mississauga, ON) was used to rescue the λgt10lacZ DNA. Phage particles were mixed with host bacterium (Escherichia coli lacZ − , galE − , recA − , pAA119 with galT and galK) and lacZ mutants selected by plating on minimal medium with 0.3% (w/v) P-Gal. Total plaque-forming units (pfu) were enumerated under non-selective conditions (i.e. titre plates without P-Gal). All plates were incubated overnight at 37°C. Mutant frequency was calculated as the ratio of mutant pfu to total pfu and analysis of mutant frequency data was performed as described previously (10) . The protocols followed those are recommended by the Organization for Economic Cooperation and Development Test Guideline (no. 488) (15) .
The frequency of lacZ transgene mutants in hepatic DNA samples from B[a] P-treated mice was determined previously using an identical protocol and is described by Malik et al. (10) .
CALUX assay B[a]P and DB[a,h]
A used for the CALUX assay were purchased from Moltox Inc. (Boone, NC). H1L1.1c2 cells are a mouse hepatoma cell line that was stably transfected with a construct containing the xenobiotic response element associated with the promoter of a luciferase reporter gene (16) . H1L1.1c2 cells were cultured in α minimum essential medium media (Invitrogen, Burlington, ON) supplemented with 10% (v/v) fetal bovine serum (Invitrogen). Exposures were carried out as described in a study by Garrison et al. (16) ; however, a 4-h exposure period was used. Cells were treated with media containing 0.1% (v/v) of the compound (B[a]P or DB[a,h]A) dissolved in dimethyl sulphoxide (DMSO) (Sigma, Oakville, ON). At least five concentrations were tested in triplicate for each compound, along with a simultaneous solvent control of 0.1% DMSO. Following the exposure period, the treatment media was removed and cells were lysed with 1× passive lysis buffer (Promega, Madison, WI) for 20 min. The cell lysate was then frozen at −80°C until protein and luciferase quantification. The BioRad Quickstart Bradford protein assay (Hercules, CA) was employed to quantify protein levels in each cell lysate according to the manufacturer's directions in a clear 96-well plate. The luciferase assay was conducted using the Promega luciferase assay kit, as per package instructions. Using Veritas software (v. 1.9.2) connected to a Veritas microplate luminometer (Turner BioSystems, Sunnyvale, CA), 100 µl of luciferase substrate was injected into each well and each well was read for 10 s, following a 2-s interval after injection. The values obtained from the luminometer are presented as relative light units (RLU). RLU per mg protein was calculated using the results of the Bradford protein assay and plotted against concentration. Non-linear, iterative least-squares modelling was employed to fit the data to a model with parameters that reflect the maximum response and the concentration required to reach one half maximum (Km), using SAS version 9.2. Model significance was determined using the F ratio. Parameter estimates for each compound were compared using student's t-test.
Total RNA isolation, hybridisation and analysis
Total RNA was extracted from liver samples using TRIzol reagent (Invitrogen, Carlsbad, CA). Samples were purified and DNase treated using RNeasy Mini Kits (Qiagen, Mississauga, ON). The A 260/280 ratio for all the RNA samples was ≥2. RNA integrity was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies). Samples with RNA integrity numbers between 8.7 and 9.4 were used for analysis. All experimental procedures were conducted according to the manufacturer's protocol (Agilent Technologies). An Agilent Fluorescent Linear Amplification kit was used in this experiment. For complementary RNA labelling, 200 ng of each experimental sample was labelled with Cyanine 5-CTP, whereas universal reference total RNA (Agilent Technologies) was labelled with Cyanine 3-CTP. Samples were hybridised to SurePrint G3 Mouse GE 8x60K microarrays (Agilent Technologies). Arrays were scanned using an Agilent G2505B scanner. Data were extracted using Feature Extraction software version 10.7.3.1. A block design (17) was used to analyse mRNA expression microarray data as described in a study by Malik et al. (10) . Briefly, the data were normalised using LOWESS in R. Outliers were identified for the raw and normalised data using ratio-intensity plots and heat maps. The microarray analysis of variance (MAANOVA) library in R was used to determine differentially expressed transcripts. The permutation method using residual shuffling was used to estimate the P-values for all statistical tests, followed by adjustment for multiple comparisons using the false discovery rate (FDR) approach. Significant genes were selected based on a FDR-adjusted P-value ≤ 0.05 for any DB[a,h]A exposed versus control contrast.
Gene expression data for mice exposed to B[a]P are described in a study by Malik et al. (10) . Gene expression profiles were derived and analysed previously using identical methods to those described above.
miRNA isolation, hybridisation and analysis RNA was extracted again from the same liver samples used for the gene expression analysis in order to obtain sufficient high-quality miRNA for analysis. MirVana miRNA isolation kits (Ambion, Streetsville, ON) were used for total RNA isolation according to the manufacturer's recommendations. The A 260/280 ratio for all of the RNA samples was approximately 2.1, with RNA integrity numbers between 8.4 and 9.8. MirVana total RNA samples (100 ng) from all experimental samples were labelled, hybridised and washed according to Agilent's protocol (Agilent Technologies). Agilent's miRNA complete labelling and hybridisation kit was used in the experiment (Agilent Technologies). Labelled samples were hybridised to mouse miRNA 8 × 15K microarrays (Agilent Technologies). Scanning and data acquisition were conducted as described above. miRNA microarray analysis was conducted as described previously (10) . Briefly, cyclic LOWESS was used to normalise non-background subtracted raw data. Box plots and cluster analyses were used to identify potential outliers. The Fs statistic was applied to test for differences between controls and DB[a,h]A-treated samples. Significant miRNAs were selected based on a FDR-adjusted P-value ≤ 0.05 for any DB[a,h]A exposed versus control contrast. Multivariate analysis of microarray data in Microarray Analysis of Ecological Data: Exploratory and Euclidean methods in Environmental sciences (MADE4) (18) was used for cluster analysis of miRNA data.
The miRNA expression data for B[a]P-treated mice were derived previously using an identical method to that described above. The full methodologies are available in a study by Malik et al. (10) .
Pathway-specific real-time-PCR analysis
A custom-made real-time (RT)-PCR array was designed for validation; procedures were performed according to the manufacturer's recommendations (SA Biosciences, Frederick, MD, USA; catalogue number CAPM10784). RT-PCR was done on a CFX96 real-time detection system (Bio-Rad, Mississauga, ON). C t values for each well were normalised to Hrpt, Actb and Nono reference mRNAs. Differential expression was determined using R software by applying a two-sample bootstrap test (19) . The resulting P-values were then FDR adjusted (20) . The fold change was estimated using the ratio of the arithmetic mean of the treated samples to the mean of the control samples. Standard errors for the fold-change values were estimated using the bootstrap method (19) .
RT-PCR validation of miRNA
The Qiagen miScript PCR system was used to validate the expression of miR34a. The procedure was performed as described previously (10) . RT-PCR was performed in duplicate for each sample using a CFX96 real-time detection system (Bio-Rad). Expression levels of miR-34a were normalised to reference RNU1 expression. Statistical analysis was by student's t-test.
Bioinformatics
All normalised and raw mRNA and miRNA microarray data have been deposited in the NCBI Gene Expression Omnibus (GEO) ID: GSE35509. Data quality was evaluated in GeneSpring GX version 11.5.1 (Agilent Technologies). Following normalisation, differentially expressed mRNAs were further analysed using Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, CA, USA) and Kyoto Encyclopedia for Genes and Genomes (KEGG) pathways and Gene Ontology (GO) terms that were enriched were identified using the Database for Annotation, Visualization and Integrated Discovery (DAVID) (21) . All significant genes were further investigated using GeneCards V3 and literature searches.
BMDExpress (22) was used to determine transcriptional benchmark doses (BMD) for genes and pathways. BMDs are calculated by modelling the doseresponse curve for a biological effect, followed by identification of a defined level of response over that observed in controls. To calculate pathway BMDs, the gene list was filtered to identify genes that were statistically significant by one-way analysis of variance (ANOVA) (P < 0.05). The Hill, power, linear 1° and polynomial 2° models were applied to the data with the following restrictions: (i) the power model had a power restriction of ≥1; (ii) selection of the linear 1° and polynomial 2° was based on choosing a model that describes the data with the least complexity; (iii) a nested chi-square test with cut-off of 0.05 was used to first select between linear and polynomial models, followed by selecting the curve with the lowest Akaike's Information Criterion; (iv) the Hill model was excluded if the 'k' parameter of the model was less than one-third of the lowest positive dose (23) . Specific settings included 250 maximum iterations, a confidence level of 0.95, and a benchmark response of 1.349 (number of standard deviation defining BMD) (22) . The BMDs for genes were mapped to KEGG pathways. BMDs that exceeded the highest exposure dose and had a goodness-of-fit P-value < 0.1 were removed from the analysis.
Results
Exposure to 6.25, 12.5 or 25 mg/kg/day DB[a,h]A for 28 days did not result in any obvious signs of toxicity in any of the mice upon necropsy and no animals exhibited significant weight loss compared with controls. No significant changes in liver weights were observed compared with controls (data not shown). Immunohistochemistry revealed that DB[a,h]A treatment resulted in an increase in cell proliferation (Table I) . ANOVA showed a marginal treatment effect (F = 3.02, P = 0.06) and post hoc comparisons with control (one-way Dunnett) showed a significant increase at 6.25 mg/kg/day only.
In our previous study, no signs of overt toxicity or weight loss were observed in B[a]P-treated mice (10). Immunohistochemistry was not performed on the livers of mice treated with B[a]P. lacZ mutant frequency A significant overall treatment effect on liver lacZ mutant frequency was found (chi-square analysis for DB[a,h]A concentration effect = 31.3, P < 0.0001), with a dose-dependent increase in lacZ mutant frequency in DB[a,h]A-exposed animals ( Figure 1C ). Exposure to the medium and high doses (12.5 and 25 mg/kg/day) caused a statistically significant increase in lacZ mutant frequency compared with controls (P < 0.0001). No statistically significant difference was observed for the lowdose group (6.25 mg/kg/day). Mutant frequency was 3.7-fold above control at 25 mg/kg/day. A strong correlation between adduct frequency and lacZ mutant frequency was also observed (r = 0.740, P < 0.05).
The mutant frequency of mice treated with B[a]P was published previously in a study by Malik et al. (10) . Briefly, a dose-dependent increase in liver mutant frequency was found, reaching a peak of 35.6-fold above control levels at the highest dose of B[a]P tested (75 mg/kg/day). The mutant frequency was significantly elevated by 4.0-fold above controls at the 25 mg/kg/day dose.
CALUX assay
The CALUX assay (Table II) were directly associated with cancer (supplementary Table 2 , available at Mutagenesis Online). The KEGG pathway for circadian rhythm was significantly enriched (Benjamini Hochberg corrected P < 0.001). Clock (circadian locomotor output cycles kaput), Arntl (aryl hydrocarbon receptor nuclear translocator like) and Per2 (period homolog 2) (from the circadian rhythm pathway), as well as AhR, Pparα (peroxisome proliferator activator receptor alpha) and Pparδ (peroxisome proliferator activator receptor delta), were among the top 15 upstream regulators based on statistical significance in the high dose group (P ≤ 0.0001). In-depth analysis of the high dose group revealed the response of genes in four main categories: circadian rhythm, glucose metabolism, lipid metabolism and cell cycle/apoptosis. A detailed overview of the responsive genes in these categories is found in Table III . A number of genes from different functional groups were validated using RT-PCR arrays (supplementary Table 3 , available at Mutagenesis Online) and demonstrate that the changes measured by the microarrays are reproducible.
Comparison of DB[a,h]A and B[a]P gene expression data
Microarray data for B[a]P-exposed mice were deposited in GEO under accession number GSE24910 and are described in detail in a study by Malik et al. (10 There were 135 probes that had signal intensities above the negative control probes (i.e. were expressed). The majority of the changes were very small (i.e. <1.2 fold). The only miRNA that exhibited a fold change ≥ 1.5 with FDR-adjusted P ≤ 0.05 in response to 12.5 and 25 mg/kg/day DB[a,h]A treatment was miR-34a (Table IV) . RT-PCR results support this finding and indicate significant up-regulation of miR-34a even at the lowest dose (6.25 mg/kg/day) of DB[a,h]A exposure ( Figure 2) .
Discussion
In the present study, we applied toxicogenomics to investigate the genes and biological functions that are affected in the livers of mice treated sub-chronically with DB[a,h]A, in parallel with analysis of cellular proliferation, DNA adduct formation and mutation induction. Muta™Mouse males exposed to DB[a,h]A for 28 days exhibited significant increases in DNA damage and mutation and experienced substantial changes in gene expression at the highest dose. The results were compared with data from the same strain/sex of mice exposed to B[a]P using a similar protocol in order to provide a broad overview of similarities and differences between these two prototypical PAHs. Table 1 , available at Mutagenesis Online). However, the expression of many genes increased in a dose-dependent manner but did not meet the conservative FDR-adjusted statistical threshold used in our study (used to minimise false positives). Thus, our estimate of impacts in the low-dose range is conservative. The vast majority of the genes that responded at the low dose were also affected at the highest dose.
DB[a,h]A treatment caused a dose-dependent increase in
Major changes in gene expression were observed following treatment with 25 mg/kg/day DB[a,h]A; 135 genes were up-regulated and 104 genes were down-regulated (fold change ≥ 1.5; FDR P ≤ 0.05; supplementary Table 1, available at Mutagenesis Online). The tissues in this study were collected 3 days post-exposure; thus, we likely missed genes that are regulated via the initial interaction of DB[a,h]A with the AhR. This is consistent with our results for B[a]P using the same sampling time (10) and the lack of AhR being identified as an upstream regulator in the IPA analysis. Indeed, a previous study reported that DB[a,h]A exposure resulted in the upregulation of CYP1A1 24 h after the exposure (64) . Although the sampling time was not ideal to identify early events in the mechanisms underlying toxicity, DB[a,h]A interaction with the Relative miR-34a expression determined using the Qiagen miScript PCR system (*P < 0.05 compared with corresponding control).
AhR was apparent in the gene expression profiling nonetheless and included induction of phosphatidylinositol transfer protein, cytoplasmic 1 (Pitpnc1) and 6-phosphofructo-2-kinase/ fructose-2,6-biphosphatase 3 (Pfkfb3) ( Other genes involved in xenobiotic metabolism that were upregulated in the livers of DB[a,h]A-treated mice included (i) Por (cytochrome P450 oxidoreductase), an electron donor for all microsomal CYP enzymes (66) and (ii) three Fmo (flavincontaining monooxygenase) family members (1, 2 and 3). Fmo metabolises various foreign chemicals, including drugs, pesticides and dietary components (67) .
The remainder of this study will focus on the various biological processes and molecular functions that were greatly affected by DB[a,h]A including circadian rhythm, glucose metabolism, lipid metabolism, cell cycle arrest and apoptosis, and immune response and inflammation. Similarities and differences between B[a]P and DB[a,h]A are described.
Circadian rhythm
Circadian clocks are biological oscillators with a multilayered regulatory network of over 200 genes involved in regulating various transcription factors, protein turnover and small-molecule feedback. Many key clock components are transcription factors that are tightly integrated with networks involved in metabolism. The transcription factor Clock plays a crucial part in homeostasis by regulating many rate-limiting genes in a number of pathways including insulin signalling, cell cycle, folic acid biosynthesis, lipid metabolism and xenobiotic metabolism (24) . Recently, we reported the activation of circadian rhythm in mice following an acute (3-day) exposure to 150 mg/kg/day B[a]P (68) . Given the different experimental designs, direct comparison to the present experiment is inappropriate. However, the finding warrants mention because changes in the expression of clock genes in both studies were largely consistent for seven genes: Per1 (period homolog 1), Per2 and Per3; Cry2 (cryptochrome 2 [photolyase-like]); Bhlhe40 (basic helix-loop-helix family, member e40); Clock; and Arntl (68) (Table III, circadian rhythm). In addition, 2,3,7,8-tetrachlorodibenzo-p-dioxin, a very potent AhR agonist, also disrupts some Clock genes leading to alterations in behavioural circadian rhythm [reviewed in a study by Shimba and Watabe (69)].
DB[a,h]A treatment affected 10 core circadian rhythm genes in our study, including both rhythmic transcriptional activators and repressors that play a crucial part in cellular homeostasis and diseases (Table III, circadian rhythm; supplementary Table 2 , available at Mutagenesis Online) (24) . Mtnr1a (melatonin receptor 1A) was also down-regulated by DB[a,h]A treatment. Mtnr1a encodes a receptor with high affinity for melatonin and is widely recognised for its role in sleep and circadian rhythm regulation (Table III, circadian rhythm; Supplementary Table 2, available at Mutagenesis Online) (25) . A newly identified Clock output gene, Nampt (nicotinami dephosphoribosyl transferase), was up-regulated in a dose-dependent manner by DB[a,h]A treatment (Table III , circadian rhythm). The dysregulation of the Nampt gene has been implicated in the susceptibility and pathogenesis of cancer, diabetes, atherosclerosis, rheumatoid arthritis, and aging (70) . Finally, a number of additional circadian-regulated genes that are involved in glucose and lipid metabolisms were also perturbed including: Pklr (pyruvate kinase liver and red blood cell), Lpl (lipoprotein lipase) and Pparδ (24) . These are discussed in detail below.
It has been established that there is cross-talk between the AhR signalling and circadian rhythm signalling pathways (69, 71) . Indeed, the master regulator Arntl shows high homology to the AhR dimerisation partner Arnt and the AhR is known to be under circadian control [reviewed in a study by Shimba and Watabe (69)]. Thus, it has been speculated that activated AhR may influence some control over circadian rhythm. Published information suggests that AhR agonistic activities may act in coordination with circadian rhythm genes to broadly influence various potentially adverse health outcomes relating to behaviour, metabolic disease and cancer. We note that four of the affected circadian rhythm genes are also implicated in cancer (supplementary Table 2 , available at Mutagenesis Online). The potential contribution of circadian rhythm perturbations to the carcinogenicity of various PAHs is supported by epidemiological and animal studies demonstrating that shift work and altered day-night cycles contribute to increased cancer incidence [reviewed in a study by Dickerman and Liu (72) and by Royh (73)]. Thus, the impact of perturbation in this pathway by PAHs on cancer outcome should be investigated in more detail.
Glucose metabolism DB[a,h]A treatment led to the dysregulation of genes involved in glucose metabolism, glucose intake and insulin homeostasis. A literature review of the altered genes suggests that these perturbations could lead to an increase in glycolytic flux and cell proliferation. This theory is supported by the suppression of Igfbp1 (insulin-like growth factor binding protein 1); Pdk4 (pyruvate dehydrogenase kinase isoenzyme 4); Fgf21 (fibroblast growth factor 21); Appl1 (adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1); Ppp1r3c (protein phosphatase 1, regulatory (inhibitor) subunit 3C); Pparδ and the induction of Pklr and Pfkfb3 (supplementary Table 1 , available at Mutagenesis Online; Table III , glucose metabolism; for a literature review on the function of these genes, please see supplementary Figure 3 , available at Mutagenesis Online). This is also supported by the increased cellular proliferation measured by the Ki67 immunohistochemistry assay for DB[a,h]A-treated mice (Table I ). In addition, St3gal5 (ST3 beta-galactoside alpha-2,3-sialyltransferase 5) was up-regulated in a dose-dependent manner by DB[a,h]A (Table III ,, glucose metabolism). This gene catalyses the formation of ganglioside GM, an inducer of insulin resistance [reviewed in a study by Inokuchi (28) ]. Thus, our data suggest that DB[a,h]A may perturb glucose and insulin balance.
In contrast to DB[a,h]A, B[a]P treatment did not result in the induction of glycolytic genes (10) . It has previously been proposed that chronic exposure to PAHs plays a role in the induction of type 2 diabetes in mice via the initiation of proinflammatory cytokine production (74) . In our study, we show that exposure to at least one PAH (DB[a,h]A) might lead to the initiation of diabetes via direct dysregulation of genes involved in glycolysis.
Lipid metabolism
Excess intracellular free fatty acid (FFA) can disrupt phospholipid bilayer membrane integrity and alter lipid signalling pathways. To avoid FFA toxicity, fatty acids (FA) are esterified with glycerol to produce mono-, di-(MG, DG), and TG, which are deposited in lipid droplets (75) . Unlike our B[a]P study (10) (Table III , lipid metabolism), which is known to be critical in lipid trafficking regulation in hepatocytes. The protein product of this gene has been implicated in the efflux of dietary sterols from the liver to the bile duct where they are excreted into the faeces via the bile, but that is only accomplished in the presence of Abcg8. Biliary cholesterol secretion was reduced by 75% in Abcg5 and/or Abcg8 knockout mice (35) . The results suggest that DB[a,h]A treatment may result in the dysregulation of biliary cholesterol secretion via up-regulating the expression of Abcg5 without its obligate heterodimer Abcg8.
DB[a,h]A treatment appears to cause lipotoxicity by affecting genes involving lipogenesis, TG hydrolysis, lipid utilisation via mitochondrial oxidation, and lipid trafficking and excretion (supplementary Figure 4 , available at Mutagenesis Online). Perturbations in these pathways can result in lipid overload and hepatocellular damage. This process is recognised as nonalcoholic fatty liver disease and can progress to the more severe non-alcoholic steatohepatitis. The latter is characterised by the presence of fatty liver inflammation (two pro-inflammatory genes were induced by DB[a,h]A and will be discussed later), the precursor of liver cirrhosis and a known risk factor for hepatocellular carcinoma (76) .
Cell cycle and apoptosis
Maintaining genomic integrity and protecting the cell from DNA damage via triggering cell cycle arrest, DNA repair and apoptosis are the most well-characterised functions of Tp53 (77) . Although DB[a,h]A treatment did not impact Tp53 transcription, it affected downstream Tp53 targets. We observed similar results in our B[a]P study (10) . The lack of changes in Tp53 transcription likely occurs because (i) the transcription factor is functionally activated via posttranslation modification and the transcript is relatively stable (77) or (ii) p53 mRNA was induced at an earlier time point (supported by the up-regulation of a number of Tp53 targets; supplementary Table 6A , available at Mutagenesis Online). Three genes involved in a Tp53 feedback loop were induced in a dose-dependent manner by DB[a,h]A treatment: Ccng1 (cyclin G1), Usp2 (ubiquitin specific peptidase 2) and Trim24 (tripartite motif-containing 24) (Table III , cell cycle and apoptosis; for literature review on the function of these genes, please see supplementary Figure 5 , available at Mutagenesis Online) (46, 50, 51, 77) . The data suggest that Tp53 may be actively degraded via this process. Active degradation of Tp53 indicates that the cells have responded to the DNA damage and that this process is no longer required. However, an increase in pro-Tp53 degrading genes could also contribute to tumour promotion; the transcriptional profiles indicate the activation of cell cycle arrest genes, the induction of apoptotic genes and the down-regulation of anti-apoptotic genes (discussed below), suggesting that the cells are still under stress. In addition, we note that there remains significantly elevated DNA adduct levels at this time point.
Collectively, our results indicate that DB[a,h]A exposure results in DNA adduct formation leading to the activation of a DNA damage response. This response is characterised by cell cycle arrest and apoptosis, which is consistent with hepatic responses in mice exposed acutely and sub-chronically to B[a] P (10, 68) . DB[a,h]A treatment appears to dysregulate cell cycle machinery resulting in the inhibition of G1/S and G2/M progression via dysregulation of Ccnb1 (cyclin B1), Wee1 (wee 1 homolog 1), Gadd45a (growth arrest and DNA-damageinducible 45 alpha), Ptp4a1 (protein tyrosine phosphatase 4a1) and Cdkn1a (cyclin-dependent kinase inhibitor 1A) (Table III, The DNA damage caused by DB[a,h]A treatment also resulted in the induction of genes associated with apoptosis (Table III , cell cycle and apoptosis). A number of apoptotic genes were up-regulated including Bnip3 (BCL2/adenovirus E1B interacting protein 3) (53), Aifm2 (apoptosis-inducing factor, mitochondrion-associated 2) (54), P2ry1 (purinergic receptor P2Y, G-protein coupled 1) (48), Ccno (cyclin O) (56) and Aen (apoptosis enhancing nuclease) (49) . The only apoptotic gene that was down-regulated was Bok (BCL2-related ovarian killer protein) (Table III , cell cycle and apoptosis) (60) . Four anti-apoptotic genes were also down-regulated in the livers of DB[a,h]A-treated mice: Cflar (CASP8 and FADD-like apoptosis regulator) (57), Atf5 (activating transcription factor 5) (61), Bcl6 (B-cell CLL/lymphoma 6) (62) and Bcl7c (B-cell CLL/lymphoma 7c) (58) . Thus, hepatic expression profiles from DB[a,h]A-treated mice suggest the induction of cell cycle arrest and apoptosis via both Tp53-dependent and Tp53-independent mechanisms. This result is similar to our observations in mice treated with B[a]P (10). Although DNA damage and apoptosis were affected by both chemicals, the spectrum of responding genes was quite different. The overall DNA damage responses were different for the two PAHs. (77) . Alterations in Cdkn1a could be a contributing factor for the observed increase in cell proliferation in this study (Table I) .
Other functional groups
The immunosuppressive effects of many PAHs have been known for many years (78) . In the present study, DB[a,h] A exposure resulted in a dose-dependent down-regulation of five genes involved in immune response: Nfil3 (nuclear factor, interleukin 3, regulated), Spon2 (spondin 2), Rnf125 (ring finger protein 125), Lag3 (lymphocyte-activation gene 3) and Raet1e (retinoic acid early transcript 1E). In parallel, two pro-inflammatory genes were up-regulated: Ltb4r1 (leukotriene B4 receptor 1) and Msr1 (macrophage scavenger receptor 1) (supplementary Table 6B , available at Mutagenesis Online). Interestingly, Adamdec1 (ADAM-like, decysin 1), an immune response gene that is implicated in cancer (supplementary Table 2 , available at Mutagenesis Online) that was induced in response to B[a]P treatment (10), was also significantly up-regulated by DB[a,h]A at the 25 mg/kg/day dose (supplementary Table 1 , available at Mutagenesis Online). Thus, our gene expression data support that DB[a,h]A also exhibits immunosuppressive effects and provide mechanistic context for the genes involved in this effect.
Mir-34a expression
Despite robust changes in gene expression, only one miRNA was affected by DB[a,h]A treatment: miR-34a (Figure 2 ). This result is remarkably consistent with our B[a]P study, where only miR-34a expression was significantly up-regulated in all doses in a dose-dependent manner in vivo after 28 days of exposure (10) . The miRNA expression results in both studies support the notion that there is very little effect of bulky DNA adducts on liver miRNAs following acute and sub-chronic exposures. Also, in both studies the miR-34a response mirrored DNA adduct formation and mutation induction, suggesting that miR34a might be a sensitive indicator of DNA damage response. MiR-34a is encoded by its own transcript, which is contained within the second exon of an expressed sequence tag that has a Tp53 binding site located ~30 kb upstream of the mature miR34a (79) . MiR-34a is up-regulated following Tp53 activation and may be required for Tp53-mediated tumour suppression. Genes involved in a number of pathways have been identified as miR-34a targets. These pathways include cell cycle arrest, senescence and apoptosis (79, 80) .
Conclusions
In conclusion, this study demonstrates that sub-chronic oral treatment with DB[a,h]A results in the formation of fewer DNA adducts than B[a]P at the same dose but similar induction of mutation. However, perturbations in gene expression are much greater following exposure to DB[a,h]A. These differences may be mediated via AhR-driven mechanisms, which is supported by the higher potency of DB[a,h]A in the CALUX assay. Three days post-exposure, there was little overlap in the biological functions and molecular processes perturbed by B[a]P and DB[a,h]A exposure. Commonalities include a DNA damage response leading to induction of cell cycle arrest and apoptosis in both Tp53-dependent and Tp53-independent manners. In addition, acute B[a]P exposure (higher doses) caused broadly similar responses in the circadian rhythm pathway as chronic DB[a,h]A exposure. As with B[a]P, miRNAs were not responsive in the livers of mice treated sub-chronically with DB[a,h]A, with the exception of miR-34a. DB[a,h]A treatment appears to cause detrimental changes in cellular homeostasis; expression profiles suggest that these changes may favour an increase in glycolysis and cell proliferation, lipotoxicity and immunosuppression. Many of the genes involved in these processes are also implicated in cancer, although DB[a,h]A treatment does not lead to cancer in the liver per se.
Although the liver is not the target organ for cancer following DB[a,h]A treatment, we elected to compare hepatic profiles following PAH treatment because the liver is the largest internal solid organ in the body and plays a central role in metabolism, energy production and homeostasis. It is also a key metabolic site for the biotransformation of PAHs. For these reasons, we believe the liver is a key target organ for analysis of pathway perturbations using toxicogenomics approaches. DB[a,h]A exposure primarily induces skin tumours, sarcomas, fibro-sarcomas, pulmonary tumours, lung adenoma and lung carcinoma in experimental animals [reviewed in a study by IARC (2)]; these tissues warrant additional attention.
A limitation of the present study is that only one time point was investigated. To better understand the initial gene expression responses that contribute to downstream toxicities occurring post-DB[a,h]A treatment and to more effectively map differences between B[a]P and DB[a,h]A, the effects on gene expression should also be explored at earlier time points for both toxicants. Future work should include immunohistochemistry analysis to investigate if a change in cell proliferation is part of the initial response to treatment for B[a]P exposures as well. A follow-up chronic in vivo study will shed light on the role of long-term DB[a,h]A exposure in the development of insulin resistance, diabetes and cancer.
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